Temsirolimus
From Wikipedia, the free encyclopedia
Temsirolimus
|
|
Systematic (IUPAC) name | |
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S, 23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24, 25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy- 3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- 1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexameth 3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28, 29(4H,6H,31H)-pentone 4′-[2,2-bis(hydroxymethyl)propionate] | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Licence data |
, |
Pregnancy cat. |
? |
Legal status | |
Routes | Intravenous |
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007,[1] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).[2] The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.